CNBioXYZ

REGN5381 Hypertension Trial Terminated

Regeneron Pharmaceuticals has discontinued the Phase 2 NATRIX-SBP study (NCT06833190) evaluating REGN5381 in uncontrolled hypertension. The trial enrolled 34 pt before termination.
This marks the 2nd MNC to abandon this target, following Novartis's earlier exit.

Betta Pharma Files for Hong Kong IPO, Valued at RMB 24.5B on SZSE

Betta Pharma Files for Hong Kong IPO, Valued at RMB 24.5B on SZSE

Sirius Therapeutics Files for Hong Kong IPO, With Two siRNA Phase 2 Assets Targeting FXI and Lp(a).

Sirius Therapeutics Files for Hong Kong IPO, With Two siRNA Phase 2 Assets Targeting FXI and Lp(a).

Merck has initiated a Phase 1 clinical trial (NCT07089784) of the oral drug MK-2828 in patients with type 2 diabetes mellitus (T2DM), with a planned enrollment of 64 participants.

Merck Initiates Phase 1 Trial (NCT07089784) of Oral MK-2828 (GLP-1?) in Patients with T2DM $MRK #Hansoh $NVO $LLY

CTTQ has submitted an ANDA for fruquintinib (Fruzaqla) in China, possibly in preparation for market entry after the patent expires in 2028.

CTTQ has submitted an ANDA for fruquintinib (Fruzaqla) in China, possibly in preparation for market entry after the patent expires in 2028. Tables might turn — will CTTQ's Anlotinib be next? $HCM $TAK

Novartis filed an IND application for PKN605 in patients with atrial fibrillation in China, aiming to enhance its presence in the cardiovascular area.

Novartis Seeks IND Clearance for PKN605 in China. #Novartis #PKN605 #AF

Bayer has filed the NDA for the HER2 inhibitor BAY 2927088 in China, with both Breakthrough Therapy Designation (BTD) and priority review status, just two months after the U.S. submission.

Bayer Files HER2i BAY 2927088 NDA in China. #Bayer #HER2 #China

BeOne has terminated the clinical trial of DGKζ inhibitor BGB-30813 due to safety concerns, following a study halt last year. The compound would likely be removed from the pipeline, despite its inclusion in the R&D Day presentation just last month.

BeOne has terminated the clinical trial of DGKζ inhibitor BGB-30813 due to safety concerns.

Sunho initiates a Phase II/III trial of IBB0979 (a B7-H3/IL-10 immunocytokine) combined with topotecan versus topotecan alone in relapsed small cell lung cancer, targeting enrollment of 200 patients.

IBB0979 enters Phase II/III study in relapsed SCLC, combo with topotecan. #SUNHO

BMS has filed its first China IND for BMS-986340 (Acceptance No. JXSL2500124), aiming for future development.

BMS has submitted its first IND application in China for BMS-986340, an investigational anti-CCR8 monoclonal antibody. $BMY $ZLAB $ONC

Puhe Biopharma Submits IND Application in China for WRN Inhibitor PH027 Targeting MSI-H Tumors. $NVS $GSK $RHHBY

FrontPage

Pipeline

Valuation

Hemay Pharmaceutical Files for Hong Kong IPO After 3.9B RMB Valuation in December Round

Pipeline

Frontpage

Sinotau International Pharmaceutical files for a Hong Kong IPO. #RLT #SSTR #PSMA

Beigene temporarily halted the first-in-human trial of BGB-A3055 (#CCR8) due to a sponsor decision, not a change in the safety or benefit-risk balance. Last November, Zai Lab also halted its anti-CCR8 antibody ZL-1218 due to safety reasons.

Frontpage

Pipeline

Valuation

Insilico Medicine files for a Hong Kong IPO, with its latest post-money valuation at $1.331 billion.

HER2-DAC TERMINATION

Orum Therapeutics discontinued HER2-DAC development after an internal assessment of its clinical status. #degrader

First page

Pipeline

Valuation

Suzhou Ribo Life Science (瑞博生物) files for a Hong Kong IPO with a post-Series E2 financing valuation of 4.8 billion RMB.

The next generation anti-nectin-4 ADC LY4052031 study (NCT06465069) is on hold because Eli Lilly called it off. It's about advanced urothelial or other solid tumors.

Live now meetings.asco.org/abstracts-pr...

#ASCO25 release abstract titles today. Meeting.asco.org

SpringWorks Pipeline

MapKure, a joint venture between SpringWorks and BeiGene, has officially terminated the development of its RAF dimer inhibitor BGB-3245 (brimarafenib) following a funding halt driven by strategic business considerations. $SWTX $ONC

Annoroad Gene Technology files for HONG KONG IPO. #IVD

Merck has suspended the Phase 1 trial of #M5542, a CD80, CD86, and OX40L antagonist developed for autoimmune diseases, citing sponsor-related reasons. #NCT06577337

Mabwell (Shanghai) Bioscience has applied for an IPO in Hong Kong.

Hengrui Pharmaceuticals files for the Hong Kong IPO.

Due to a business decision, Astellas terminated the phase 1 study of CD20 autologous convertible CAR-T ASP2802. #NCT06248086 #Xyphos

Haixi Pharmaceuticals files for HONG KONG IPO.

Bristol Myers Squibb (BMS) initiates a phase 1/2 trial of BMS-986490 (anti-CEACAM5) in the pts with solid tumor. #NCT06730750 $BMY $SNY

Innogen Pharmaceutical files for HK IPO. #GLP1

Notes: SciWind filed BLA for Ecnoglutide, XW003 in November.

IDEAYA's DNA Helicase Werner Inhibitor (WRNi) IDE275 (GSK4418959) Enters the Phase 1/2 Trial. $IDYA $GSK #NCT06710847